secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000465
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon prioritizes kidney transplant program for tegoprubart; Phase 1b data expected Q1 2023
--------------------------------------------------------------------------------

- Ph 1b kidney transplant trial enrollment ongoing; initial 3- and 6-month data at World Congress of Nephrology March 2023.
- FDA cleared IND for Phase 2 BESTOW trial (tegoprubart vs tacrolimus, ~120 patients); site initiation mid-2023.
- Deprioritizing tegoprubart in IgAN and discontinuing islet cell trial to focus resources on kidney transplantation.
- Cash resources sufficient to fund operating activities into 2024 (no specific amount given).
- Collaboration with eGenesis for preclinical xenotransplantation studies using tegoprubart.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023000465/0000950170-23-000465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023000465/eldn-20230109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer